Effectiveness of metformin as an adjunctive therapy in rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials
Abstract
Background: Rheumatoid arthritis (RA) is a chronic inflammatory disease that impacts patients' quality of life. Evidence regarding the effectiveness of metformin use as an adjunct therapy in RA is limited and fragmented. This systematic review and meta-analysis aimed to evaluate the effectiveness of metformin as an adjunct therapy in RA and to quantitatively synthesize available evidence.
Methods: This systematic review and meta-analysis were conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, focusing on randomised controlled trials (RCTs) that assessed the effect of metformin as an adjunct therapy for patients with RA receiving conventional synthetic disease-modifying antirheumatic drugs (csDMARDs). C-reactive protein (CRP), Disease Activity Score in 28 joints (DAS-2)8, and Health Assessment Questionnaire Disability Index (HAQ-DI) were included as an outcome. A search was conducted across four databases up to 31 December 2025, including PubMed, Embase, Cochrane Central, and Scopus. The methodological quality of the included RCTs was evaluated using risk of bias 2 (RoB 2) tool. Statistical analysis was conducted with StataNow version 19.5. For each outcome, pooled mean differences (MDs) with 95% confidence intervals (CIs) were estimated using random-effects models.
Results: A total of four RCTs with 350 participants were included in this review. The use of metformin was associated with significant decreases in…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 350 participants or records.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.